We expect SRF's pharmaceuticals business to boost growth of specialty chemicals in 2HFY17, driven by the commencement of commercial production of new molecules at its multi-purpose plant. The company also has 10-20 molecules under R&D; and is optimistic about commercializing them in future. On the other hand, slowdown in its agrichem business (accounting for almost 75% of revenues) globally continues to impact the specialty chemicals business. Thus, we expect growth in specialty chemicals to be lower than its historical run-rate, but maintain...